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The endocannabinoid 2-arachidonoylglycerol (2-AG)
is a retrograde lipid messenger that modulates syn-
aptic function, neurophysiology, and behavior. 2-AG
signaling is terminated by enzymatic hydrolysis—a
reaction that is principally performed by monoacyl-
glycerol lipase (MAGL). MAGL is broadly expressed
throughout the nervous system, and the contribu-
tions of different brain cell types to the regulation of
2-AG activity in vivo remain poorly understood.
Here, we genetically dissect the cellular anatomy of
MAGL-mediated 2-AG metabolism in the brain and
show that neurons and astrocytes coordinately regu-
late 2-AG content and endocannabinoid-dependent
forms of synaptic plasticity and behavior. We also
find that astrocytic MAGL is mainly responsible for
converting 2-AG to neuroinflammatory prostaglan-
dins via a mechanism that may involve transcellular
shuttling of lipid substrates. Astrocytic-neuronal
interplay thus provides distributed oversight of
2-AG metabolism and function and, through doing
so, protects the nervous system from excessive
CB1 receptor activation and promotes endocannabi-
noid crosstalk with other lipid transmitter systems.INTRODUCTION
Historical neuron-centric conceptualizations of brain function
have given way to a deeper appreciation of the important roles
played by additional brain cell types in regulating chemical trans-
mission throughout the nervous system (McIver et al., 2013).
Astrocytes are now recognized as integral components of syn-
apses and central regulators of neurotransmission and inter-
neuronal communication (Halassa and Haydon, 2010). Astroglial798 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authorstransporters clear neurotransmitters, such as glutamate and
g-amino butyric acid (GABA), from synaptic clefts to modulate
the signaling activities of these chemical messengers and limit
their toxic accumulation in the extracellular space (Danbolt,
2001). Metabolic pathways in astrocytes are also essential for
the recycling and resupply of neurotransmitters needed to main-
tain sustained rounds of synaptic activity (Coulter and Eid, 2012).
Moreover, defects in astrocytic functions that lead to alterations
in the homeostasis of major neurotransmitters have been linked
to a variety of mental and neurodegenerative disorders (Allaman
et al., 2011; Halassa and Haydon, 2010). Microglia, which are
resident immune cells of the nervous system, also contribute
to neurotransmission through activity-dependent remodeling
and pruning of synapses (Salter and Beggs, 2014; Schafer
et al., 2012). Efforts to elucidate the contributions of glia to the
regulation of synaptic function therefore stand to both enrich
our mechanistic understanding of intercellular communication
in the brain and provide new therapeutic avenues for the treat-
ment of diverse neurological conditions.
The endogenous cannabinoid (endocannabinoid or eCB)
2-arachidonoylglycerol (2-AG) is an arachidonic acid (AA)-
derived retrograde lipid messenger that broadly modulates
synaptic function throughout the nervous system (Fowler et al.,
2005; Kano et al., 2009; Pacher et al., 2006). 2-AG is synthesized
by diacylglycerol lipases (DAGLs) (Reisenberg et al., 2012) and
released in an activity-dependent manner from postsynaptic
neurons to act on presynaptic G-protein-coupled cannabinoid
receptors CB1 (CB1R) and CB2, which are also targets of the
primary psychoactive component of marijuana (D9-tetrahydro-
cannabinol) (Mechoulam and Hanus, 2000). Principally through
its activity on CB1Rs, 2-AG inhibits neurotransmitter release
and regulates diverse neurophysiological processes, including
mood, nociception, appetite, and memory (Pacher et al.,
2006). Enzymatic hydrolysis of 2-AG, which is primarily mediated
by monoacylglycerol lipase (MAGL) in the nervous system (Dinh
et al., 2002; Ueda et al., 2013), terminates CB1R-dependent
signaling (Chanda et al., 2010; Schlosburg et al., 2010; Zhong
et al., 2011) and concomitantly provides a major source of AA
for brain eicosanoid synthesis (Nomura et al., 2011). The DAGL
and MAGL enzymes thus tightly regulate 2-AG-mediated neuro-
transmission and have historically been viewed as doing so
through their respective expression in the pre- and post-synaptic
compartments of neurons (Di Marzo et al., 2015). Glial cells may
also serve as cellular substrates for the modulation of 2-AG,
however, as both astrocytes and microglia release this eCB
and express CB1Rs (Navarrete and Araque, 2008, 2010; Stella,
2010; Walter et al., 2004; Witting et al., 2004). Furthermore,
ectopic expression of MAGL in Bergmann glia has been shown
to attenuate 2-AG-dependent retrograde synaptic suppression
in cerebellar slices from MAGL/ mice (Tanimura et al., 2012).
Nonetheless, the relative contributions of neurons and glia to
the termination of 2-AG-dependent synaptic and neurobehavio-
ral functions, as well as the potential for crosstalk between these
cell types to facilitate the recycling and homeostasis of eCB-
eicosanoid pools, remain largely unexplored.
Global pharmacological or genetic disruption of MAGL
robustly elevates brain 2-AG content (Chanda et al., 2010;
Long et al., 2009; Schlosburg et al., 2010), alters CB1R-mediated
signaling and behaviors (Chanda et al., 2010; Long et al., 2009;
Schlosburg et al., 2010; Zhong et al., 2011), and impairs neuro-
inflammation through mechanisms that involve eCB-eicosanoid
crosstalk (Nomura et al., 2011). With the goal of determining the
relative contribution of different brain cell types to 2-AG meta-
bolism and signaling in vivo, we report the generation and char-
acterization of a conditional genetic mousemodel used to ablate
MAGL globally and specifically in neurons, astrocytes, and mi-
croglia. We discover that neuronal and astrocytic MAGL coordi-
nately regulate brain 2-AG content, contribute to the termination
of synaptic 2-AG signaling at CB1Rs, and, by doing so, maintain
a balanced eCB tone that protects against desensitization
caused by excessive signaling. Moreover, we show that
astrocytic MAGL is principally responsible for generating
2-AG-derived arachidonate pools used for the synthesis of
pro-inflammatory prostaglandins in the brain. Finally, we provide
evidence for the transcellular shuttling of 2-AG and related me-
tabolites between neurons and astrocytes as one mechanism
by which these cells can coordinately regulate eCB-eicosanoid
pathways in the nervous system. The distributed metabolism
of 2-AG across both neurons and astrocytes thus affords the
nervous system more refined control over dynamic features
of eCB activity, including protection against desensitization
and facilitating crosstalk with other lipid transmitter systems
that are deregulated in disease states.
RESULTS
Cell-Type-Specific Deletion of MAGL in the Nervous
System
To examine the contribution of different brain cell types to 2-AG
metabolism and signaling in vivo, we generated a genetic mouse
model forconditionaldeletionof theMAGLenzymebyflanking the
catalytic exon of theMgll gene (exon 4, containing catalytic S122)
with loxP recombination sites (MAGLloxP, Figures 1A and S1A–
S1C). The MAGLloxP line was initially validated by crossing to
mice that ubiquitously express Cre recombinase (Rosa26-Cre;
Otto et al., 2009) to produce total MAGL/ mice (MAGL-TKO).Consistent with previous reports for other conventional MAGL/
lines (Chanda et al., 2010; Schlosburg et al., 2010), MAGL-TKO
mice lacked detectable MAGL expression and activity across
different central and peripheral tissues and cell types (Figures
1B–1E and S1D). MAGL-TKO mice also exhibited marked
(90%) reductions in brain 2-AG hydrolysis (Figure 1F), as well
as 10-fold elevations in brain 2-AG content (Figure 1G).
We next crossed homozygous MAGLloxP mice to mice with
restricted expression of Cre recombinase in neurons (Eno2-Cre;
Frugier et al., 2000), astrocytes (GFAP-Cre; Tao et al., 2011), or
microglia (LysM-Cre; Clausen et al., 1999) to generate mouse
lines that lack MAGL specifically in these three brain cell
types (MAGL-NKO, MAGL-AKO, andMAGL-MKO, respectively).
Crossing of Eno2-, GFAP-, and LysM-cre mice to a Cre-inducible
Rosa26-tdTomato reporter line validated efficient Cre-mediated
recombination throughout the brain of these animals, selectively
in neurons, astrocytes, and microglia, respectively (Figure S1E).
While the Eno2- and GFAP-Cre lines produced Cre-mediated
recombination in the vast majority (80–90+%) of neurons and
astrocytes, respectively (with the GFAP-Cre line also showing
low-level (2%–6%) recombination in neurons, consistent with
previous studies; Tao et al., 2011), the LysM-Cre line only ap-
peared to promote Cre-mediated recombination in 50%–60%
of Iba1-positive microglia in the brain. Cultured preparations of
brain cells (Figure S1F and S1G), however, confirmed selective
and near-complete loss of MAGL expression in microglia from
MAGL-MKOmice, aswell as in neurons (GABAergicandglutama-
tergic; Figure S1H) and astrocytes from MAGL-NKO and MAGL-
AKO, respectively (Figure1B). Importantly, eachMAGL-disrupted
brain cell type also displayed significantly reduced 2-AG hydro-
lytic activity, although the relative magnitude of this decrease
was greater for neurons compared to astrocytes or microglia,
possibly due to the presence of additional 2-AG hydrolases in
glia (Marrs et al., 2010; Figure 1C).
Having establishedmousemodels that display selective lossof
MAGL in different brain cell types, we next examined how neu-
rons, astrocytes, and microglia contribute to bulk 2-AG meta-
bolism in the nervous system. Deletion of MAGL in both neurons
and astrocytes, but not microglia, substantially reduced the total
quantity of active enzyme inbrain tissue, asmeasuredby activity-
based protein profiling (ABPP; Figures 1D and 1E). These data
mirrored the effects on brain 2-AG hydrolysis, which was
decreased by 60% and 40% in MAGL-NKO and MAGL-AKO
mice, respectively, but unaltered inMAGL-MKOmice (Figure 1F).
Notably, both MAGL-NKO and MAGL-AKO mice displayed sig-
nificant (5- and 3-fold, respectively) increases in brain 2-AG
(Figure 1G). No changes in brain 2-AG content were found in
MAGL-MKO mice. Finally, none of the conditional MAGL/
mouse lines displayed alterations in anandamide (AEA) (Fig-
ure 1H), a secondmajor eCB that is principally hydrolyzedby fatty
acid amide hydrolase (Cravatt et al., 1996). These data, taken
together, indicate that both neuronal and astrocytic MAGL
make substantial contributions to 2-AG metabolism in the brain.
Neuronal and Astrocytic MAGL Regulate
eCB-Dependent Synaptic Plasticity
2-AG functions as a major retrograde synaptic messenger that
suppresses neurotransmitter release after binding to presynapticCell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 799
Figure 1. Brain Cell Type-Specific Deletion
ofMAGL Identifies Both Neurons and Astro-
cytes as Key Regulators of 2-AG Meta-
bolism in the Nervous System
(A) Diagram of the targetedMgll locus in MAGLloxP
mice, in which the catalytic exon 4 of this enzyme
is flanked by loxP recombination sites (GHSMG
sequence containing the catalytic serine nucleo-
phile is shown). When MAGLloxP mice are crossed
with mice that express Cre recombinase, exon 4 is
excised to produce the null allele (MAGL).
(B) Western blot of neurons, astrocytes, and
microglia derived from MAGL-TKO (T, total),
MAGL-NKO (N, neuron), MAGL-AKO (A, astro-
cyte), or MAGL-MKO (M, microglia) mice confirms
efficient and cell-type-specific depletion of MAGL
in these different mouse lines.
(C) 2-AG hydrolytic activities of neuron, astrocyte,
and microglia membrane proteomes derived from
MAGL-TKO (T), MAGL-NKO (N), MAGL-AKO (A),
and MAGL-MKO (M) mice confirms cell-type-
specific loss of MAGL in these different mice. n =
4–5 per cell type and genotype. Error bars repre-
sent SEM; **p < 0.01 versus MAGL+/+ samples.
(D and E) SDS-PAGE readout of an activity-based
protein profiling (ABPP) analysis of brain mem-
brane proteomes from MAGL-TKO (T), MAGL-
NKO (N), MAGL-AKO (A), and MAGL-MKO (M)
mice using a serine-hydrolase-directed fluo-
rophosphonate-rhodamine probe (Cravatt et al.,
2008) (fluorescent gel shown in grayscale) (D).
Quantification of MAGL band intensity is shown
(E). n = 4–5 mice per genotype. Error bars repre-
sent SEM; **p < 0.01 versus MAGL+/+ samples.
(F) 2-AG hydrolytic activities of MAGL-TKO (T),
MAGL-NKO (N), MAGL-AKO (A), and MAGL-MKO
(M) brain membrane proteomes. n = 4–5 mice per
genotype. Error bars represent SEM; **p < 0.01
versus MAGL+/+ samples.
(G and H) Brain levels of 2-AG (G) and anandamide
(AEA, H) in MAGL-TKO (T), MAGL-NKO (N),
MAGL-AKO (A), and MAGL-MKO (M) mice. n = 8
mice per genotype. Error bars represent SEM;
**p < 0.01 versus MAGL+/+ samples.
See also Figure S1.CB1Rs (Kano et al., 2009). Various forms of synaptic plasticity are
regulated by retrograde eCB signaling, including depolarization-
induced suppression of excitation (DSE) and inhibition (DSI)
(Kano et al., 2009). Complete genetic or pharmacological abla-
tion of MAGL activity significantly prolongs DSE/DSI (Pan et al.,
2009; Straiker et al., 2009; Zhong et al., 2011), and the selective
ablation of MAGL in cerebellar granule cells also extends DSE,
but to a lesser degree than global ablation of the enzyme (Tani-
mura et al., 2012). To more clearly delineate the relative control
that different brain cell types exert over 2-AG-dependent forms
of synaptic plasticity, we initially examined DSE at parallel fiber
(PF) to Purkinje cell (PC) synapses in acute cerebellar slices pre-
pared from the different conditional MAGL-knockout lines.
A brief depolarization of PCs induced robust transient DSE at
PF-PC synapses in MAGL+/+ cerebellar slices (Figures 2A–2C).
Consistent with previous reports (Tanimura et al., 2012; Zhong
et al., 2011), global deletion of MAGL substantially prolonged
the duration (Figure 2A), but not magnitude (Figure S2A), of800 Cell Reports 12, 798–808, August 4, 2015 ª2015 The AuthorsDSE at PF-PC synapses in MAGL-TKO mice. A less dramatic
but significant DSE extension was also observed in cerebellar
slices from MAGL-NKO mice (Figure 2B). Notably, cerebellar
slices from MAGL-AKO mice also showed a significant prolon-
gation in DSE (Figure 2C) that was nearly identical in total
duration to that observed in MAGL-NKO slices, as indicated
by changes in the mean decay time constant (t) (Figure 2D).
No differences in DSE were evident in MAGL-MKO mice
(Figure S2B).
We further examined the contributions of neurons and astro-
cytes to CB1R-mediated forms of synaptic plasticity by assess-
ing DSI at CA1 pyramidal neuron synapses in hippocampal slices
prepared fromMAGL-TKO, MAGL-NKO, andMAGL-AKO, mice,
as well as their wild-type littermates. DSI was readily induced in
MAGL+/+ CA1 pyramidal neurons by applying a brief depolariza-
tion while evoking inhibitory postsynaptic currents (IPSCs)
through stimulation of synaptic inhibitory inputs (see Experi-
mental Procedures; Figures 2E–2G). Consistent with previous
Figure 2. Astrocytic and Neuronal MAGL
Play Complementary Roles in Terminating
Retrograde 2-AG Signaling
(A–C) Average time courses of PF-EPSCs in
response to a brief depolarization in cerebellar
slices prepared from MAGL-TKO (A), MAGL-NKO
(B), and MAGL-AKO (C) mice and their wild-type
littermates show prolonged DSE following global,
neuron- or astrocyte-specific loss of MAGL.
Sample traces are shown for MAGL-TKO mice.
n = 14–18 cells from n = 3 mice per genotype.
(D) Time constant (t) of DSE in cerebellar slices
prepared from MAGL-TKO (T), MAGL-NKO (N),
and MAGL-AKO (A) mice and their wild-type lit-
termates. n = 14–18 cells from n = 3 mice per
genotype. Error bars represent SEM; *p < 0.05,
**p < 0.01, ***p < 0.001 versus MAGL+/+.
(E–G) Average time courses of IPSCs in CA1
pyramidal neurons in response to a brief depo-
larization in hippocampal slices prepared from
MAGL-TKO (E), MAGL-NKO (F), and MAGL-AKO
(G) mice and their wild-type littermates show
prolonged DSI following global, neuron- or astro-
cyte-specific loss of MAGL. Sample traces are
shown for MAGL-TKO mice. n = 13–15 cells from
n = 3 mice per genotype.
(H) Time constant (t) of DSI in hippocampal slices
prepared from MAGL-TKO (T), MAGL-NKO (N),
and MAGL-AKO (A) mice and their wild-type
littermates. n = 13–15 cells from n = 3 mice per
genotype. Error bars represent SEM; *p < 0.05,
**p < 0.01 versus MAGL+/+.
See also Figure S2.reports (Pan et al., 2011), the duration of hippocampal DSI in
MAGL-TKOmicewas substantially prolonged (Figure 2E). Signif-
icant, albeit less dramatic, extensions in DSI were also observed
in hippocampal slices from MAGL-NKO and MAGL-AKO mice
(Figures 2F and 2G), both of which displayed similar increases
in t (Figure 2H).
These findings, taken together, indicate that astrocytes and
neurons both play prominent roles in terminating 2-AG signaling
at synaptic terminals, and, as a result, dramatic increases in the
duration of CB1R activation are only observed when MAGL is
deleted from both brain cell types.Cell Reports 12, 798–80Neuronal and Astrocytic MAGL
Regulate Functional CB1R
Adaptations In Vivo
Chronic, global inactivation of MAGL,
achieved by either genetic disruption
or repeated treatment with a MAGL
inhibitor, has been shown to produce
behavioral tolerance in pain models,
cross-tolerance to exogenous cannabi-
noids, and desensitization and downre-
gulation of brain CB1Rs (Chanda et al.,
2010; Schlosburg et al., 2010). In agree-
ment with these earlier reports, we found
that the antinociceptive and hypothermic
effects of the CB1R agonist WIN55,212-2were substantially attenuated in MAGL-TKO mice compared to
their wild-type littermates (Figures 3A and 3B). No evidence of
cross-tolerance to WIN55,212-2 was observed in either MAGL-
NKO orMAGL-AKOmice (Figures 3C–3F). Correlating with these
behavioral data, MAGL-TKO mice, but not MAGL-NKO or
MAGL-AKO mice, showed a dramatic reduction in brain CB1R
function, as measured by CB1R agonist (CP55,940)-stimulated
[35S]-GTPgS binding (Figures 3G–3I). These results indicate
that expression of MAGL in either neurons or astrocytes is suffi-
cient to prevent excessive activation and corresponding desen-
sitization of brain CB1Rs in vivo, highlighting the contribution that8, August 4, 2015 ª2015 The Authors 801
Figure 3. Astrocytic and Neuronal MAGL Maintain a Balanced eCB
Tone to Protect against CB1R Desensitization
(A–F) Antinociceptive and hypothermic effects of full CB1R agonist
WIN55,212-2 in MAGL-disrupted mice. MAGL-TKOs (A and B), but not MAGL-
NKO (C and D) or MAGL-AKOs (E and F), display significant cross-tolerance to
WIN55,212-2-induced antinociception and hypothermia. n = 7–8 mice per
group. Error bars represent SEM; *p < 0.05 and **p < 0.01 versus wild-type
littermates.
(G–I) CP55,940-stimulated [35S]-GTPgS binding in hippocampal homogenates
from MAGL-TKO, MAGL-NKO, and MAGL-AKO mice presented as concen-
tration-effect curves (G) and Emax (H) or EC50 (I) values determined by non-
linear regression. n = 5 mice per group assayed in triplicate. Error bars
represent SEM; **p < 0.01 versus MAGL+/+ samples.both cell types make to 2-AG metabolism and the maintenance
of eCB signaling tone.
Astrocytes Are Critical Mediators of eCB-Eicosanoid
Crosstalk
MAGL serves as a metabolic hub linking eCB and eicosanoid
signaling pathways in the brain, where the hydrolysis of 2-AG
provides a major source of AA substrate for prostaglandin
synthesis (Nomura et al., 2011). MAGL blockade has been
shown to coordinately elevate 2-AG and lower eicosanoid con-802 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authorstent in the nervous system under basal and neuroinflammatory
states, including in disease models of parkinsonism and Alz-
heimer’s disease (Chen et al., 2012; Nomura et al., 2011; Piro
et al., 2012). Despite these advances in our understanding of
eCB-eicosanoid crosstalk, how this interplay is enacted at the
cellular level in the nervous system remains unknown. We set
out to address this important question by first assessing the
integrity of the eCB-prostaglandin network in individual brain
cell types. Cultured neurons lacking MAGL showed significant
elevations in 2-AG and reductions in AA, but, interestingly, did
not produce detectable levels of prostaglandins (Figures 4A–
4C). In contrast, MAGL/ astrocytes, while displaying a more
modest relative increase in 2-AG compared to neurons, proved
capable of translating their heightened eCB content into
corresponding reductions in AA and prostaglandins (Figures
4A–4C). These findings indicate that individual brain cell types,
despite expressing prostaglandin biosynthetic enzymes in
culture (Hewett et al., 2000; Ikeda-Matsuo et al., 2005), differ in
their capacity to autonomously convert eCBs to prostaglandins,
raising the possibility that this process involves transcellular
metabolism in vivo.
A broader analysis of brain lipids revealed that, as expected
based on previous studies (Nomura et al., 2011), global inactiva-
tion of MAGL not only elevated 2-AG but also lowered AA and
prostaglandins (Figure 4D). MAGL-TKO mice also displayed
markedly blunted induction of prostaglandin synthesis following
lipopolysaccharide (LPS) administration compared to their
MAGL+/+ littermates (Figure 4D). In contrast, MAGL-NKO mice,
despite showing 5-fold elevations in brain 2-AG, exhibited
negligible changes in AA or prostaglandin content under basal
conditions or following LPS treatment (Figure 4E). MAGL-AKO
mice, on the other hand, while exhibiting amoremodest increase
in brain 2-AG (3-fold), showed significantly reduced brain AA
content and attenuated prostaglandin production following
LPS treatment (Figure 4F). Basal changes in brain prostaglandins
were not observed in MAGL-AKO mice and the magnitude of
decrease in these eicosanoids following LPS treatment was
less substantial than that observed in MAGL-TKO mice (Figures
4D and 4F).
LPS treatment, in addition to inducing brain prostaglandin
synthesis, stimulates an acute neuroinflammatory response as
reflected in microglial activation and cytokine production.
Consistent with previous findings, MAGL-TKOmice showed sig-
nificant reductions in LPS-induced brain cytokines andmicroglial
activation compared to MAGL+/+ littermates (Figure S3A–S3D).
These neuroinflammatory markers were, however, not altered
in MAGL-NKO mice (Figures S3E–S3H). MAGL-AKO mice
showed an intermediate phenotype, with modest but significant
reductions in LPS-induced brain cytokine and unaltered micro-
glial activation compared to MAGL+/+ mice (Figures S3I–S3L).
Consistent with the absence of changes in bulk brain lipids in
MAGL-MKO mice, these animals displayed no alterations in
LPS-induced prostaglandin and cytokines production or micro-
glial activation (Figures S4A–S4D). We did find, however, that
cultured MAGL/microglia were impaired in producing prosta-
glandins and also displayed substantially reduced in vitro inflam-
matory responses (Figures S4E and S4F), consistent with recent
reports (Pihlaja et al., 2015). It is possible that incomplete removal
Figure 4. Astrocytes Hydrolyze 2-AG to Generate AA Precursor Pools for Pro-inflammatory Prostaglandin Production
(A–C) 2-AG (A), AA (B), and PGDE2/D2 (C) levels in MAGL
+/+ and MAGL/ neurons and astrocytes. N, neurons; A, astrocytes.; N.D., not detectable. n = 5 per cell
type and genotype. Error bars represent SEM; **p < 0.01 versus corresponding MAGL+/+ cells.
(D–F) Brain levels of 2-AG, AA, PGE2, and PGD2 in MAGL-TKO (D), MAGL-NKO (E), and MAGL-AKO (F) mice following administration of vehicle or LPS (20 mg/kg
intraperitoneally, 6 hr). n = 6–8 mice per genotype and treatment. Error bars represent SEM; *p < 0.05 and **p < 0.01 versus corresponding MAGL+/+ vehicle
treated; #p < 0.05 and ##p < 0.01 versus MAGL/ vehicle treated; &p < 0.05 and &&p < 0.01 versus MAGL+/+ LPS treated.
See also Figures S3 and S4.of MAGL from all brain microglia in the MAGL-MKO mice (Fig-
ure S1E) prevented observation of a contribution from micro-
glia-derived MAGL to neuroinflammatory responses in vivo.
Taken together, our in vitro and in vivo data provide strong ev-
idence that eCB-eicosanoid crosstalk depends on the coordi-
nated metabolic activities of neurons and astrocytes, with the
former cell type providing robust production of 2-AG and the
latter possessing the capacity to convert this eCB into prosta-
glandins. As such, robust anti-neuroinflammatory effects were
only observed following global (versus cell-type-specific) dele-
tion of MAGL, supporting a central role for neuronal-astrocytic
crosstalk in the regulation of eCB-eicosanoid networks in the
nervous system under pathological conditions.
Neuronal-Astrocytic Transcellular Shuttling of 2-AG and
Related Metabolites
Bidirectional shuttling of conventional neurotransmitters (e.g.,
glutamate and GABA) and their metabolic products betweenneurons and glia is an established mechanism by which distinct
cellular pools of these chemical messengers and their signaling
activities can be regulated (Coulter and Eid, 2012). We postu-
lated that 2-AG and/or 2-AG-derived metabolites might partici-
pate in a similar mode of intercellular transfer between neurons
and astrocytes, which could provide a mechanism to rebalance
bioactive lipid pools across these two cell types. To investigate
this possibility, we measured 2-AG and related metabolites in
MAGL+/+ and MAGL/ neurons grown by themselves or co-
cultured with astrocytes in transwell dishes with polycarbonate
membrane-permeable supports, which permitted free exchange
of secreted metabolites in the absence of cell-cell contact. We
found that, when cultured alone,MAGL/ neurons accumulated
and released higher amounts of 2-AG compared to MAGL+/+
neurons and experienced a corresponding depletion
in intracellular AA content (Figures 5A and 5B). In the presence
of MAGL+/+ astrocytes, however, MAGL/ neurons showed
smaller relative elevations in intracellular and, especially,Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 803
Figure 5. Transcellular Shuttling of 2-AG
and AA between Neurons and Astrocytes
(A and B) Intracellular (A) and media (B) 2-AG and
AA levels from MAGL+/+ and MAGL/ neurons
cultured alone () or in the presence of astrocytes
(+) in transwell co-culture dishes. n = 5 per geno-
type. Error bars represent SEM; **p < 0.01 versus
MAGL+/+. ##p < 0.01 versus MAGL/ neurons
cultured without astrocytes.
(C and D) Intracellular endogenous (gray bars) and
d8-labeled (black bars) 2-AG and AA levels from
MAGL+/+ and MAGL/ neurons and MAGL+/+
astrocytes co-cultured together for 36 hr following
direct labeling of only one of the two cell types with
AA-d8. AA-d8 is readily incorporated into intracel-
lular lipid pools of both neurons and astrocytes (C)
and is transferred to co-cultured cells that have
not themselves directly received AA-d8 (D). n = 5
per genotype. Error bars represent SEM; *p < 0.05
and **p < 0.01 versus corresponding MAGL+/+
cells.
(E) Endogenous and d8-labeled 2-AG and AA
levels in media from MAGL+/+ and MAGL/
neurons and MAGL+/+ astrocytes co-cultured
together for 36 hr following direct AA-d8 labeling of
only one of the two cell types. n = 5 per genotype.
Error bars represent SEM; **p < 0.01 versus cor-
responding MAGL+/+. ##p < 0.01 versus labeled
astrocytes.secreted 2-AG, and attenuated reductions in intracellular AA
content (Figures 5A and 5B). Deletion of MAGL did not affect
secreted AA, although the absolute quantity of this lipid was
higher in the media of neuron/astrocyte co-cultures compared
to isolated neurons (neuron MAGL+/+ = 128 ± 89; neuron
MAGL/ = 125 ± 12; co-culture MAGL+/+ astrocytes/MAGL+/+
neurons = 326 ± 19; co-culture MAGL+/+ astrocytes/MAGL/
neurons = 298 ± 43 pmol/mg protein; Figure 5B). Together, these
data indicated that astrocytes can take up 2-AG released from
neurons and may, in turn, deliver 2-AG-derived metabolites
(e.g., AA) back to neurons.
We next used metabolic labeling methods to examine in more
depth the bidirectional shuttling of AA-derived metabolites
between neurons and astrocytes. AA-d8 added to media was
readily incorporated into intracellular lipids of either neurons or804 Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authorsastrocytes in culture, including 2-AG
(2AG-d8) (Figure 5C) and other pools of
neutral lipids and phospholipids (e.g.,
18:0, 20:4 DAG-d8, 18:0, 20:4 PS-d8;
d8-labeled prostaglandins were not
detected, presumably due to their low
abundance; Figures S5A and S5B). AA-
d8-labeled astrocytes and neurons were
then co-cultured with ‘‘naı¨ve’’ neurons
or astrocytes, respectively, in transwell
dishes (36 hr co-culture; see Methods),
which resulted in extensive incorporation
of AA-d8 in the naive cells (Figures 5D,
S5C, and S5D). Examination of media
from these co-cultures revealed thatAA-d8-labeled neurons released higher amounts of 2AG-d8
compared to AA-d8-labeled astrocytes, which preferentially
secreted free AA-d8 (Figure 5E). Of note, AA-d8-labeled
MAGL/ neurons accumulated and released more 2-AG-d8
than AA-d8-labeled MAGL
+/+ neurons (Figures 5C and 5E),
resulting in higher uptake and metabolism of this eCB by neigh-
boring ‘‘naı¨ve’’ astrocytes (Figures 5D and S5D). Even without
being directly labeled with AA-d8, MAGL
–/– neurons also accu-
mulated more 2-AG-d8 than MAGL
+/+ neurons when co-cultured
with AA-d8-labeled MAGL
+/+ astrocytes (Figure 5D). These data
thus provide evidence that transcellular shuttling from neurons to
astrocytes contributes to the metabolism of 2-AG, and,
conversely, astrocyte-derived AA can be returned to neurons
to rebalance the synthesis of arachidonoyl-containing lipids,
including 2-AG itself (Figure 6).
Figure 6. Distributed Oversight of 2-AG Metabolism and Function in
Neurons and Astrocytes
Proposed model of astrocytic-neuronal transcellular shuttling and metabolism
of 2-AG and AA. PIP2, phosphatidylinositol 4,5-biphosphate; PLC, phospho-
lipase C; DAG, diacylglycerol; DAGLa, diacylglycerol lipase alpha; COX, cy-
clooxygenase.DISCUSSION
Pharmacological or genetic disruption of MAGL produces pro-
found changes in synaptic plasticity, neurophysiology, and
behavior (Blankman and Cravatt, 2013; Murataeva et al., 2014),
underscoring the substantive role played by 2-AG as a lipid
transmitter in the nervous system. Considering the diverse
signaling andmetabolic functions of 2-AG, and that acute versus
chronic blockade ofMAGL often results in opposing outcomes—
reflective of heightened 2-AG-mediated agonism and functional
antagonism of CB1Rs, respectively—it stands to reason that the
enzymatic termination of this eCBwould be spatially and tempo-
rally organized in the nervous system to guard against excess
activity. One established mechanism to limit 2-AG action is the
positioning of MAGL at presynaptic terminals of neurons in close
proximity to CB1Rs (Straiker et al., 2009). Whether this subcellu-
lar distribution reflects a dominant role for neurons in the control
of 2-AG signaling capacity, however, remains unknown. By
leveraging a mouse line that imparts conditional deletion of
MAGL in specific brain cell types, we show that the metabolism
of 2-AG in vivo depends on both neurons and astrocytes and that
crosstalk between these cells modulates eCB-eicosanoid
signaling networks to affect synaptic plasticity, neuroinflamma-
tion, and neurobehavioral processes.
Some features of 2-AG metabolism and signaling were
affected to similar degrees by deletion of MAGL in neurons
and astrocytes. Selective loss of MAGL in neurons or astro-
cytes, for instance, comparably attenuated cerebellar DSE
and hippocampal DSI in comparison to MAGL-TKO mice, sug-
gesting complementary roles for these cell types in terminating
retrograde 2-AG signaling. Our findings are also consistent with
a recent study showing that heterologous expression of MAGL
in Bergmann glia reverses the prolonged cerebellar DSEobserved in global MAGL/ mice (Tanimura et al., 2012) and
extend this work in an important way by determining the func-
tion of endogenously expressed astrocytic MAGL in terminating
2-AG-mediated synaptic plasticity events in different brain re-
gions. Perhaps most strikingly, we found that selective deletion
of MAGL in either neurons or astrocytes, despite producing sig-
nificant elevations in brain 2-AG (5- and 3-fold, respectively),
averted the CB1R desensitization and behavioral tolerance
caused by global MAGL inactivation. The distributed meta-
bolism of 2-AG across neurons and astrocytes thus protects
the nervous system from adaptive changes caused by exces-
sive eCB signaling. In this manner, 2-AG metabolism appears
to differ from the cell-type-dominant inactivation observed for
more conventional neurotransmitters (e.g., astrocytes primarily
inactivate glutamate, while neurons mainly terminate GABA
signaling; Schousboe et al., 2013). We should further note that
the relative contributions of neuronal and astrocytic MAGL to
2-AG signal termination may differ at individual synapses, as
not all CB1R-positive nerve terminals express MAGL (Uchiga-
shima et al., 2011).
Our studies also uncovered distinct and complementary roles
for neurons and astrocytes in 2-AG metabolism. MAGL deletion
in neurons caused a more dramatic cellular increase in 2-AG,
which was also efficiently secreted from these cells. Neurons
in culture, however, exhibited no detectable capacity to convert
2-AG to prostaglandins. Similarly, MAGL-NKO mice, despite
having substantially elevated brain 2-AG, did not show alter-
ations in brain AA or prostaglandins under basal or neuroinflam-
matory conditions. Cultured astrocytes lacking MAGL, in
contrast, coupled elevations in 2-AG with reductions in AA
and prostaglandins. A similar lipid profile was observed for
LPS-treated MAGL-AKO mice. These data, taken together, indi-
cate that astrocytes play a major role in facilitating eCB-eicos-
anoid crosstalk in the nervous system, where they appear to
convert both autonomously generated and neuronally derived
2-AG into AA and eicosanoids, especially under conditions of
neuroinflammation. While our studies did not provide evidence
that microglia contribute to brain eCB-eicosanoid crosstalk
in vivo, it is possible that bulk tissue measurements failed to
detect more anatomically or temporally restricted roles for mi-
croglia in regulating eCB-eicosanoid networks. Likewise, other
2-AG metabolic enzymes (e.g., hydrolases [ABHD6, ABHD12;
Blankman et al., 2007; Marrs et al., 2010] and oxygenases
[COX2; Rouzer and Marnett, 2008]), as well as distinct enzy-
matic pathways for generating eicosanoids (e.g., PLA2G4A)
(Burke and Dennis, 2009), constitute additional potential modes
for metabolic regulation of eCB-eicosanoid pathways in the
brain.
How might distinct pools of 2-AG in neurons and astrocytes
be coordinately regulated and balanced? Our transwell co-cul-
ture studies indicate that both 2-AG and AA can shuttle between
neurons and astrocytes, with neurons being the main producers
of extracellular 2-AG and astrocytes converting this eCB into AA
(and presumably AA-derived metabolites) that can be returned
to neurons. We therefore propose a model in which neuronal
2-AG is hydrolyzed not only at synaptic terminals but also
by neighboring astrocytes, which then transfer AA back to neu-
rons to regenerate signaling pools of 2-AG (Figure 6). TheCell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 805
transcellular movement of 2-AG from neurons to astrocytes may
be required to couple eCB and eicosanoid pathways under
basal conditions in which selective deletion of MAGL in either
neurons or astrocytes did not alter brain prostaglandins. In the
context of neuroinflammation, however, some of the AA gener-
ated from autonomous and/or neuronal sources of 2-AG is di-
verted in astrocytes for prostaglandin synthesis (Figures 6 and
S5E). The transcellular movement of AA and AA-derived metab-
olites to facilitate eicosanoid synthesis has also been shown to
occur in select peripheral systems, such as between alveolar
epithelial cells and macrophages or platelets and neutrophils
(Folco and Murphy, 2006). Evidence has also accumulated to
support the existence of lipid-binding proteins that regulate, at
least in part, the uptake, transport, and release of 2-AG and
AA; however, the identities and precise contributions of these
proteins remain unclear (Brash, 2001; Fowler, 2013). Deter-
mining potential protein carriers and transporters that partici-
pate in neuron-astrocyte lipid shuttling represents a fertile topic
for future research. Our model further shares some organiza-
tional similarity with the glutamate-glutamine cycle, in which
synaptic glutamate is taken up by astrocytes, amidated into
glutamine, and transferred back to neurons for re-synthesis of
glutamate (Danbolt, 2001). Thus, neuron-astrocyte crosstalk ap-
pears to be a conserved mechanism for compartmentalizing
and regulating the functions of diverse synaptic modulators
that include both classical neurotransmitters and retrograde
lipid messengers.
EXPERIMENTAL PROCEDURES
For an extended section, see Supplemental Experimental Procedures.
Generation of Conditional MAGL/Mice
Mice carrying a loxP-flanked catalytic exon 4 Mgll allele for the conditional
ablation of MAGL were generated using standard gene-targeting techniques.
Homozygous MAGLloxP mice were bred to Rosa26-Cre (Otto et al., 2009),
Eno2-Cre (Frugier et al., 2000), GFAP-Cre (Tao et al., 2011), and LysM-Cre
mice (Clausen et al., 1999) to generate MAGL-TKO, MAGL-NKO, MAGL-
AKO, and MAGL-MKOs respectively.
Biochemical Studies
ABPP, substrate activity assays, and agonist-stimulated [35S]GTPgS binding
assays were performed as previously described (Schlosburg et al., 2010) using
cell membrane homogenates from 2-month-old conditional MAGL/ mice
and wild-type littermates or from primary neurons, astrocytes, and microglia.
Electrophysiology
DSE at PF to PC synapses and DSI at CA1 pyramidal neuron synapses were
examined in cerebellar and hippocampal slices, respectively from MAGL+/+
or MAGL/ mice from the different MAGL conditional lines as previously
described (Pan et al., 2009; Zhong et al., 2011).
Behavioral Assays
Two-month-old conditional MAGL/ and wild-type littermates were evalu-
ated for cannabimimetic responses (antinociception and hypothermia)
following injection with WIN55,212-2 using a cumulative dosing regimen as
described elsewhere (Schlosburg et al., 2010).
Liquid Chromatography-Mass Spectrometry Metabolite Profiling
Tissue lipid levels in 2-month-old MAGL+/+ or MAGL/mice from the different
MAGL conditional lines were measured from organic-soluble brain extracts by
targeted MRM methods (Nomura et al., 2011).806 Cell Reports 12, 798–808, August 4, 2015 ª2015 The AuthorsTranswell Co-culture Studies
Neurons and astrocytes were co-cultured in 10-cm transwell dishes with poly-
carbonate membrane permeable supports for 16 days prior to organic extrac-
tion of lipids from each cell type separately. For AA-d8 labeling experiments,
membrane permeable supports from 12 DIV co-cultures were temporarily
transferred to a separate culture dish so that either neurons or astrocytes could
be labeledwith AA-d8 conjugated to BSA (Rouzer et al., 2006). After 48 hr, cells
were thoroughly washed and returned to the original co-culture for another
36 hr prior to organic extraction of lipids from each cell type separately.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.06.075.
AUTHOR CONTRIBUTIONS
A.V., J.L.B, Q.-S.L., J.E.S., D.E.S, L.J.S, A.H.L, and B.F.C. designed the exper-
iments; A.V., J.L.B, C.M.J., P.Z., X.L., J.E.S., and A.J.T. did the experiments;
A.V., J.L.B, Q.-S.L., A.J.T, and D.E.S. analyzed data; and A.V. andB.F.C. wrote
the manuscript.
ACKNOWLEDGMENTS
We thank members of the Cravatt lab for helpful discussions and technical
assistance. This work was supported by the NIH grants DA033760,
DA032933 (B.F.C.), GM109315 (A.V.), DA037344 (J.E.S.), DA035217 and
MH101146 (Q.-S.L.), and DA030404 (L.J.S. and D.E.S.). B.F.C. is a founder
and scientific advisor to Abide Therapeutics, a biotechnology company inter-
ested in developing serine hydrolase inhibitors as therapeutics.
Received: January 21, 2015
Revised: June 1, 2015
Accepted: June 25, 2015
Published: July 23, 2015
REFERENCES
Allaman, I., Be´langer, M., and Magistretti, P.J. (2011). Astrocyte-neuron meta-
bolic relationships: for better and for worse. Trends Neurosci. 34, 76–87.
Blankman, J.L., and Cravatt, B.F. (2013). Chemical probes of endocannabi-
noid metabolism. Pharmacol. Rev. 65, 849–871.
Blankman, J.L., Simon, G.M., and Cravatt, B.F. (2007). A comprehensive
profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoyl-
glycerol. Chem. Biol. 14, 1347–1356.
Brash, A.R. (2001). Arachidonic acid as a bioactive molecule. J. Clin. Invest.
107, 1339–1345.
Burke, J.E., and Dennis, E.A. (2009). Phospholipase A2 structure/function,
mechanism, and signaling. J. Lipid Res. 50 (Suppl), S237–S242.
Chanda, P.K., Gao, Y., Mark, L., Btesh, J., Strassle, B.W., Lu, P., Piesla, M.J.,
Zhang, M.Y., Bingham, B., Uveges, A., et al. (2010). Monoacylglycerol lipase
activity is a critical modulator of the tone and integrity of the endocannabinoid
system. Mol. Pharmacol. 78, 996–1003.
Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.P., Teng, Z., and
Chen, C. (2012). Monoacylglycerol lipase is a therapeutic target for Alzheimer’s
disease. Cell Rep. 2, 1329–1339.
Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Fo¨rster, I. (1999).
Conditional gene targeting in macrophages and granulocytes using LysMcre
mice. Transgenic Res. 8, 265–277.
Coulter, D.A., and Eid, T. (2012). Astrocytic regulation of glutamate homeosta-
sis in epilepsy. Glia 60, 1215–1226.
Cravatt, B.F., Giang, D.K., Mayfield, S.P., Boger, D.L., Lerner, R.A., and Gilula,
N.B. (1996). Molecular characterization of an enzyme that degrades neuromo-
dulatory fatty-acid amides. Nature 384, 83–87.
Cravatt, B.F., Wright, A.T., and Kozarich, J.W. (2008). Activity-based protein
profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Bio-
chem. 77, 383–414.
Danbolt, N.C. (2001). Glutamate uptake. Prog. Neurobiol. 65, 1–105.
DiMarzo, V., Stella, N., and Zimmer, A. (2015). Endocannabinoid signalling and
the deteriorating brain. Nat. Rev. Neurosci. 16, 30–42.
Dinh, T.P., Carpenter, D., Leslie, F.M., Freund, T.F., Katona, I., Sensi, S.L.,
Kathuria, S., and Piomelli, D. (2002). Brain monoglyceride lipase partici-
pating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA 99,
10819–10824.
Folco, G., and Murphy, R.C. (2006). Eicosanoid transcellular biosynthesis:
from cell-cell interactions to in vivo tissue responses. Pharmacol. Rev. 58,
375–388.
Fowler, C.J. (2013). Transport of endocannabinoids across the plasma mem-
brane and within the cell. FEBS J. 280, 1895–1904.
Fowler, C.J., Holt, S., Nilsson, O., Jonsson, K.O., Tiger, G., and Jacobsson,
S.O. (2005). The endocannabinoid signaling system: pharmacological and
therapeutic aspects. Pharmacol. Biochem. Behav. 81, 248–262.
Frugier, T., Tiziano, F.D., Cifuentes-Diaz, C., Miniou, P., Roblot, N., Dierich, A.,
Le Meur, M., and Melki, J. (2000). Nuclear targeting defect of SMN lacking the
C-terminus in a mouse model of spinal muscular atrophy. Hum. Mol. Genet. 9,
849–858.
Halassa, M.M., and Haydon, P.G. (2010). Integrated brain circuits: astrocytic
networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72,
335–355.
Hewett, S.J., Uliasz, T.F., Vidwans, A.S., and Hewett, J.A. (2000). Cyclooxyge-
nase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in
primary cortical cell culture. J. Pharmacol. Exp. Ther. 293, 417–425.
Ikeda-Matsuo, Y., Ikegaya, Y., Matsuki, N., Uematsu, S., Akira, S., and Sasaki,
Y. (2005). Microglia-specific expression of microsomal prostaglandin E2 syn-
thase-1 contributes to lipopolysaccharide-induced prostaglandin E2 produc-
tion. J. Neurochem. 94, 1546–1558.
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., andWata-
nabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission.
Physiol. Rev. 89, 309–380.
Long, J.Z., Li, W., Booker, L., Burston, J.J., Kinsey, S.G., Schlosburg, J.E.,
Pavo´n, F.J., Serrano, A.M., Selley, D.E., Parsons, L.H., et al. (2009). Selective
blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behav-
ioral effects. Nat. Chem. Biol. 5, 37–44.
Marrs, W.R., Blankman, J.L., Horne, E.A., Thomazeau, A., Lin, Y.H., Coy, J.,
Bodor, A.L., Muccioli, G.G., Hu, S.S., Woodruff, G., et al. (2010). The serine hy-
drolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid
receptors. Nat. Neurosci. 13, 951–957.
McIver, S., Faideau, M., and Haydon, P. (2013). Astrocyte–neuron communi-
cations. In Neural-Immune Interactions in Brain Function and Alcohol Related
Disorders, C. Cui, L. Grandison, and A. Noronha, eds. (Springer), pp. 31–64.
Mechoulam, R., and Hanus, L. (2000). A historical overview of chemical
research on cannabinoids. Chem. Phys. Lipids 108, 1–13.
Murataeva, N., Straiker, A., and Mackie, K. (2014). Parsing the players:
2-arachidonoylglycerol synthesis and degradation in the CNS. Br. J. Pharma-
col. 171, 1379–1391.
Navarrete, M., and Araque, A. (2008). Endocannabinoids mediate neuron-
astrocyte communication. Neuron 57, 883–893.
Navarrete, M., and Araque, A. (2010). Endocannabinoids potentiate synaptic
transmission through stimulation of astrocytes. Neuron 68, 113–126.
Nomura, D.K., Morrison, B.E., Blankman, J.L., Long, J.Z., Kinsey, S.G., Mar-
condes, M.C., Ward, A.M., Hahn, Y.K., Lichtman, A.H., Conti, B., and Cravatt,
B.F. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that
promote neuroinflammation. Science 334, 809–813.
Otto, C., Fuchs, I., Kauselmann, G., Kern, H., Zevnik, B., Andreasen, P.,
Schwarz, G., Altmann, H., Klewer, M., Schoor, M., et al. (2009). GPR30 doesnot mediate estrogenic responses in reproductive organs in mice. Biol.
Reprod. 80, 34–41.
Pacher, P., Ba´tkai, S., and Kunos, G. (2006). The endocannabinoid system as
an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389–462.
Pan, B.,Wang,W., Long, J.Z., Sun, D., Hillard, C.J., Cravatt, B.F., and Liu, Q.S.
(2009). Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacyl-
glycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)
methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabi-
noid signaling. J. Pharmacol. Exp. Ther. 331, 591–597.
Pan, B., Wang, W., Zhong, P., Blankman, J.L., Cravatt, B.F., and Liu, Q.S.
(2011). Alterations of endocannabinoid signaling, synaptic plasticity, learning,
and memory in monoacylglycerol lipase knock-out mice. J. Neurosci. 31,
13420–13430.
Pihlaja, R., Takkinen, J., Eskola, O., Vasara, J., Lo´pez-Pico´n, F.R., Haapar-
anta-Solin, M., and Rinne, J.O. (2015). Monoacylglycerol lipase inhibitor
JZL184 reduces neuroinflammatory response in APdE9 mice and in adult
mouse glial cells. J. Neuroinflammation 12, 81.
Piro, J.R., Benjamin, D.I., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M.,
Schwartz, J.W., Nomura, D.K., and Samad, T.A. (2012). A dysregulated endo-
cannabinoid-eicosanoid network supports pathogenesis in a mouse model of
Alzheimer’s disease. Cell Rep. 1, 617–623.
Reisenberg, M., Singh, P.K., Williams, G., and Doherty, P. (2012). The diacyl-
glycerol lipases: structure, regulation and roles in and beyond endocannabi-
noid signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. 367, 3264–3275.
Rouzer, C.A., and Marnett, L.J. (2008). Non-redundant functions of cyclooxy-
genases: oxygenation of endocannabinoids. J. Biol. Chem. 283, 8065–8069.
Rouzer, C.A., Ivanova, P.T., Byrne,M.O.,Milne, S.B.,Marnett, L.J., andBrown,
H.A. (2006). Lipid profiling reveals arachidonate deficiency in RAW264.7 cells:
Structural and functional implications. Biochemistry 45, 14795–14808.
Salter, M.W., and Beggs, S. (2014). Sublime microglia: expanding roles for the
guardians of the CNS. Cell 158, 15–24.
Schafer, D.P., Lehrman, E.K., Kautzman, A.G., Koyama, R., Mardinly, A.R.,
Yamasaki, R., Ransohoff, R.M., Greenberg, M.E., Barres, B.A., and Stevens,
B. (2012). Microglia sculpt postnatal neural circuits in an activity and comple-
ment-dependent manner. Neuron 74, 691–705.
Schlosburg, J.E., Blankman, J.L., Long, J.Z., Nomura, D.K., Pan, B., Kinsey,
S.G., Nguyen, P.T., Ramesh, D., Booker, L., Burston, J.J., et al. (2010). Chronic
monoacylglycerol lipase blockade causes functional antagonism of the endo-
cannabinoid system. Nat. Neurosci. 13, 1113–1119.
Schousboe, A., Bak, L.K., and Waagepetersen, H.S. (2013). Astrocytic control
of biosynthesis and turnover of the neurotransmitters glutamate and GABA.
Front. Endocrinol. (Lausanne) 4, 102.
Stella, N. (2010). Cannabinoid and cannabinoid-like receptors in microglia,
astrocytes, and astrocytomas. Glia 58, 1017–1030.
Straiker, A., Hu, S.S., Long, J.Z., Arnold, A., Wager-Miller, J., Cravatt, B.F., and
Mackie, K. (2009). Monoacylglycerol lipase limits the duration of endocannabi-
noid-mediated depolarization-induced suppression of excitation in autaptic
hippocampal neurons. Mol. Pharmacol. 76, 1220–1227.
Tanimura, A., Uchigashima, M., Yamazaki, M., Uesaka, N., Mikuni, T., Abe, M.,
Hashimoto, K., Watanabe, M., Sakimura, K., and Kano, M. (2012). Synapse
type-independent degradation of the endocannabinoid 2-arachidonoylgly-
cerol after retrograde synaptic suppression. Proc. Natl. Acad. Sci. USA 109,
12195–12200.
Tao, J., Wu, H., Lin, Q., Wei, W., Lu, X.H., Cantle, J.P., Ao, Y., Olsen, R.W.,
Yang, X.W., Mody, I., et al. (2011). Deletion of astroglial Dicer causes non-
cell-autonomous neuronal dysfunction and degeneration. J. Neurosci. 31,
8306–8319.
Uchigashima, M., Yamazaki, M., Yamasaki, M., Tanimura, A., Sakimura, K.,
Kano, M., and Watanabe, M. (2011). Molecular and morphological configura-
tion for 2-arachidonoylglycerol-mediated retrograde signaling at mossy cell-
granule cell synapses in the dentate gyrus. J. Neurosci. 31, 7700–7714.Cell Reports 12, 798–808, August 4, 2015 ª2015 The Authors 807
Ueda, N., Tsuboi, K., and Uyama, T. (2013). Metabolism of endocannabinoids
and related N-acylethanolamines: canonical and alternative pathways. FEBS
J. 280, 1874–1894.
Walter, L., Dinh, T., and Stella, N. (2004). ATP induces a rapid and pronounced
increase in 2-arachidonoylglycerol production by astrocytes, a response
limited by monoacylglycerol lipase. J. Neurosci. 24, 8068–8074.808 Cell Reports 12, 798–808, August 4, 2015 ª2015 The AuthorsWitting, A., Walter, L., Wacker, J., Mo¨ller, T., and Stella, N. (2004). P2X7 recep-
tors control 2-arachidonoylglycerol production by microglial cells. Proc. Natl.
Acad. Sci. USA 101, 3214–3219.
Zhong,P., Pan,B.,Gao, X.P., Blankman, J.L., Cravatt, B.F., andLiu,Q.S. (2011).
Genetic deletion of monoacylglycerol lipase alters endocannabinoid-mediated
retrograde synaptic depression in the cerebellum. J. Physiol. 589, 4847–4855.
Cell Reports 
Supplemental Information 
Metabolic Interplay between Astrocytes  
and Neurons Regulates Endocannabinoid Action 
Andreu Viader, Jacqueline L. Blankman, Peng Zhong, Xiaojie Liu, Joel E. Schlosburg, 
Christopher M. Joslyn, Qing-Song Liu, Aaron J. Tomarchio, Aron H. Lichtman, Dana E. 
Selley, Laura J. Sim-Selley, and Benjamin F. Cravatt 
	   2	  
 
 
 
	   3	  
Figure S1, related to Figure 1. Generation and characterization of conditional 
MAGL–/– mice. 
(A) Targeting vector used to flank Mgll exon 4 (containing catalytic S122) with loxP 
recombination sites to enable conditional Cre recombinase-mediated gene deletion. 
 (B) Identification of targeted clone no. 56 by Southern analysis of EcoRI-digested ES 
cell genomic DNA with external 5’ and 3’ probes.  
(C) Southern analysis confirmation of germ-line transmission in a chimeric male arising 
from injection of clone no.56 into albino C57BL/6 blastocysts. 
(D) Activity-based protein profiling of brain, liver, and white adipose tissue (WAT) 
membrane proteomes from MAGL-TKO mice and wild-type littermates confirms global 
loss of MAGL across different tissues in the MAGL-TKO animals. 
(E) Representative confocal images of brain sections from Rosa26-tdTomato/Eno2-Cre 
(MAGL-NKO), GFAP-Cre (MAGL-AKO), and LysM-cre (MAGL-MKO) mice co-stained 
for reporter protein tdTomato (RFP) and neuronal (NeuN), astroglial (GFAP) and 
microglial (Iba1) markers, confirm efficient, widespread, but largely cell-selective cre-
mediated recombination. Quantification of % recombination of hippocampal (Hip) and 
cerebellar (Cer) neurons, astrocytes, and microglia in Rosa26-tdTomato/Eno2-Cre, 
GFAP-Cre, and LysM-cre mice respectively is shown. Note that, as previously reported 
(Tao et al., 2011), 2-6% of neurons in Rosa26-tdTomato/GFAP-Cre   mice show cre-
mediated recombination. Scale bars 30 µm. N=2 mice per genotype.  
(F, G) Immunocytochemical (F) and western blot (G) analysis of neuron, astrocyte and 
microglia cultures with cell type-specific markers (Tuj1, GFAP, and Iba1 respectively; 
actin used to visualized all cells), confirms high degree of enrichment of cultures used to 
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examine MAGL deletion in these cell types. (H) Western blot of neurons derived from 
MAGL-TKO (T), -NKO (N), -AKO (A), or –MKO (M) mice shows that these cultures 
include both glutamatergic (glutamate receptor-expressing neurons, GluN1/NR1) and 
GABAergic neurons (GABA receptor-expressing neurons, GABAA α1), and that MAGL 
is ablated in both neuron types specifically in MAGL-TKO and -NKO mice.  
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Figure S2, related to Figure 2. Characterization of DSE properties in cerebellar 
slices from MAGL-disrupted mouse models.  
(A) Magnitude of DSE in cerebellar slices prepared from MAGL-TKO (T), -NKO (N), -
AKO (A), and –MKO (M) mice and their wild-type littermates. n=14-18 cells from N=3 
mice per genotype. Error bars represent SEM. 
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(B) Sample traces (top), average time courses (bottom) and decay time constant 
(τ, right) of PF-EPSCs in cerebellar slices prepared from MAGL-MKO mice. n=14-18 
cells from N=3 mice per genotype. Error bars represent SEM. 
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Figure S3, related to Figure 4. Astrocyte- but not neuron-specific loss of MAGL 
attenuates neuroinflammatory responses in mice.  
 (A, B; E, F; I, J) Inflammatory cytokine levels as measured by ELISA in brains from 
MAGL-TKO (A, B), MAGL-NKO (E, F), or MAGL-AKO (I, J) mice and corresponding 
wild-type littermates following administration of vehicle or LPS (20 mg/kg, i.p., 6 hours). 
N=6-8 per treatment and genotype. Error bars represent SEM; **p<0.01 vs. MAGL+/+ 
vehicle-treated; ##p<0.01 vs. MAGL–/– vehicle-treated; &&p<0.01 vs. MAGL+/+ LPS-
treated.  
(C, D; G, H; K, L) Quantification and representative pictures of microglial activation 
assessed by Iba-1 staining in hippocampal regions from MAGL-TKO (C, D), MAGL-
NKO (G, H), or MAGL-AKO (K, L) and corresponding wild-type littermates following 
administration of vehicle or LPS (1 mg/kg once per day for 4 days). Scale bar, 50 µm. 
N=5 per treatment and genotype. Error bars represent SEM; **p<0.01 vs. MAGL+/+ 
vehicle-treated; ##p<0.01 vs. MAGL–/– vehicle-treated; &&p<0.01 vs. MAGL+/+ LPS-
treated.  
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Figure S4, related to Figure 4. Microglia-specific loss of MAGL attenuates 
inflammatory responses in vitro, but does not in vivo.  
(A) Brain levels of 2-AG, AA, PGE2, and PGD2 in MAGL-MKO mice following 
administration of vehicle or LPS (20 mg/kg, i.p., 6 hours). N=6-8 mice per genotype and 
treatment. Error bars represent SEM; *p<0.05 and **p<0.01 vs. MAGL+/+ vehicle-
treated; #p<0.05 and ##p<0.01 vs. MAGL–/– vehicle-treated. 
(B) Inflammatory cytokine levels as measured by ELISA in brains from MAGL-MKO 
mice and corresponding wild-type littermates following administration of vehicle or LPS 
(20 mg/kg, i.p., 6 hours). N=6-8 per treatment and genotype. Error bars represent SEM; 
**p<0.01 vs. MAGL+/+ vehicle-treated; ##p<0.01 vs. MAGL–/– vehicle-treated.  
(C, D) Quantification (C) and representative pictures (D) of microglial activation 
assessed by Iba-1 staining in hippocampal regions from MAGL-MKO mice and 
corresponding wild-type littermates following administration of vehicle or LPS (1 mg/kg 
once per day for 4 days). Scale bar, 50 µm. N=5 per treatment and genotype. Error bars 
represent SEM; **p<0.01 vs. MAGL+/+ vehicle-treated; ##p<0.01 vs. MAGL–/– vehicle-
treated; &&p<0.01 vs. MAGL+/+ LPS-treated. 
(E) Levels of 2-AG, AA, and PGE2/D2 basally as well as after exposure to the pro-
inflammatory agent lipopolysaccharide (LPS; 100 ng/mL for 4 hours) in MAGL+/+ and 
MAGL–/– microglia. Note that pre-treatment with CB1/2R inhibitors rimonabant and 
AM630, respectively (5 µM each, 1 h pre-treatment), did not block MAGL deletion-
induced reduction in LPS-induced prostaglandin synthesis. N=5 per genotype and 
treatment.  Error bars represent SEM; **p<0.01 vs. MAGL+/+ vehicle-treated; ##p<0.01 
vs.  MAGL–/– vehicle-treated; &&p<0.01 vs.  MAGL+/+ LPS-treated. 
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(F) LPS-induced (100 ng/mL for 4 hours) inflammatory cytokine levels as measured by 
ELISA in MAGL+/+ and MAGL–/– microglia. Note that pre-treatment with CB1/2R inhibitors 
rimonabant and AM630, respectively (5 µM each, 1 h pre-treatment), did not block 
MAGL deletion-induced reduction in LPS-induced cytokine production. N=5 per 
genotype and treatment.  Error bars represent SEM; **p<0.01 vs.  MAGL+/+  vehicle-
treated; ##p<0.01 vs. MAGL–/–  vehicle-treated; &&p<0.01 vs.  MAGL+/+ LPS-treated. 
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Figure S5, related to Figure 5 and 6. Transcellular shuttling of arachidonate 
metabolites between neurons and astrocytes. 
 (A-D) Intracellular levels of endogenous (gray bars) and d8-labeled (black bars) AA-
containing lipids in MAGL+/+ and MAGL–/– neurons and MAGL+/+ astrocytes co-cultured 
together for 36 h following direct labeling of only one of the two cell types with AA-d8. 
AA-d8 is readily incorporated into intracellular lipid pools of both neurons and astrocytes 
(A, B) and is transferred to co-cultured cells that have not themselves directly received 
AA-d8 (C, D). DAG, diacylglycerol, C18:0/C20:4; PC, phosphatidylcholine C18:0/C20:4; 
PI, phosphatidylinositol C18:0/C20:4; PS, phosphatidylserine C18:0/C20:4. N=5 per 
genotype. Error bars represent SEM; *p < 0.05 and **p < 0.01 vs. MAGL+/+ cells. 
(H) Proposed model for how astrocytic-neuronal transcellular metabolism regulates 
eCB-eicosanoid crosstalk under basal and neuroinflammatory conditions. In basal 
conditions, hydrolysis of neuron-derived 2-AG in astrocytes provides a principal source 
for prostaglandin production (pink arrows), such that reductions in basal prostaglandins 
requires deletion of MAGL in both neurons and astrocytes. Following exposure to 
inflammatory stimuli, 2-AG autonomously generated in astrocytes becomes a major 
source of AA for prostaglandin synthesis (yellow arrows); hence, in states of 
neuroinflammation (e.g., LPS-treatment), reductions in brain prostaglandins are 
observed in mice with global or astrocyte-specific loss of MAGL. 	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Supplemental Experimental Procedures 
Materials. Fluorophosphonate (FP)-rhodamine was synthesized as previously described
(Patricelli et al., 2001). All deuterated lipid standards and substrates were purchased from
 Cayman Chemicals. Lipopolysaccharide from E. coli was purchased from Sigma (0111:B4).  
 
Generation of MAGLloxP mice, matings and genotyping. All animal experiments were 
carried out in compliance with institutional animal protocols, and mice were housed on a 
normal 6AM/6PM light/dark phase with ad libitum access to water and food. A MAGL 
conditional knockout construct targeting the deletion of Mgll catalytic exon 4 was 
generated by amplifying 7 and 4 kb regions of the Mgll gene adjacent to the catalytic 
exon 4 from a BAC clone containing the Mgll locus (clone ID RP23-82I13, BACPAC 
Resources, Children’s Hospital Oakland Research Institute) and subcloning 
these homologous arms into the NotI/SacII and KpnI/HpaI sites of the pKO12 vector. 
This targeting construct consisted of exon 4 flanked by loxP sites (for future excision by 
the Cre recombinase), a flrted neomycin cassette (for the positive selection of integrated 
clones following treatment with geneticin), and homologous arms of genomic DNA at 
either side (to target the construct to the genomic locus). A thymidine kinase gene-
cassette was also included just outside the homologous arms to serve as a ganciclovir-
sensitive negative selection marker against clones in which the constructs had 
integrated by non-homologous recombination. Following electroporation of the targeting 
construct in C57BL/6 Bruce 4-derived murine embryonic stem (ES) cells, ~3000 
integrated ES cell clones were obtained and screened for homologous recombination by 
Southern blot analysis with external probes located 5’ and 3’ of the targeted region. 
These probes gave differential band sizes in wild-type (22 kb) or targeted (5’ probe, 8.1 
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kb; 3’ probe, 13.9 kb) genomic DNA digested with EcoRI. One homologous 
recombinant, 56, was identified, expanded and injected into albino C57BL/6 blastocysts. 
Blastocyst implantation into pseudopregnant albino C57BL/6 females generated six 
chimeric males, two of which gave rise to germline transmission as determined by coat 
color and Southern analysis. These mice were bred to homozygocity to produce 
MAGLloxP mice (MgllloxP/loxP). MAGL-TKOs (Mgll-/-) and control littermates (Mgll+/+) were 
generated by crossing MgllloxP/loxP mice to Rosa26-Cre mice (Taconic model #12524) 
(Otto et al., 2009), backcrossing the resulting offspring heterozygous for the null allele 
with C57BL/6 mice to eliminate the Cre recombinase transgene, and then setting up 
heterozygous matings. MAGL-NKO, -AKO, and –MKO mice were generated by crossing 
MgllloxP/loxP to Eno2-Cre (Jax stock #005938) (Frugier et al., 2000), GFAP-Cre (Jax stock 
#012887) (Tao et al., 2011) and LysM-Cre (Jax stock #004781) (Clausen et al., 1999) 
mice respectively, then backcrossing the resulting double heterozygotes (Cre+/-, 
Mgll+/loxP) to MgllloxP/loxP to produce cell type-specific KOs (Cre+/-, MgllloxP/loxP) and 
littermate controls (Cre-/-, MgllloxP/loxP). Eno2-Cre, GFAP-Cre, and Lysm-Cre mice were 
also crossed to Rosa26-tdTomato reporter mice (Jax stock #007909) to validate Cre 
recombinase expression. PCR genotyping of genomic tail DNA was performed using 5’- 
ccagctaaacatgcttcatcgtcgg-3’ and 5’- ccttctctacacctgcggtgctaac-3’, which amplify a 356-
bp product in cre-expressing mice, as well as 5’- cacctgtctttggagctc ccacc-3’, 5’-
cctttctttagggagagtccactgaatgtg-3’, and 5’-ggcagcactgacaaatgtgtctgag-3’, which amplify 
a 415-bp product in wild-type mice, a 533-bp product in mice with the MAGL floxed 
allele, and a 598-bp product in mice with the MAGL null allele.   
 
Primary neuron, astrocyte, and microglia cultures. The primary cell culture protocols 
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used in this study were approved by the Scripps Research Institute Institutional Animal 
Care and Use Committee. Cortico-hippocampal neurons were prepared from embryonic 
day 18 mice from the different MAGL conditional lines as needed. Cortices/hippocampi 
were dissected, freed of meninges, and dissociated by incubation in Papain/DNase for 
20 minutes at 37 °C followed by trituration. Dissociated cortico-hippocampal neurons 
were then washed with DMEM media supplemented with 10% FBS and 2 mM 
glutamine, prior to seeding them onto poly-D-lysine coated 10 cm culture dishes in 
neurobasal medium containing 2% B27 supplement, 2 mM glutamine, and 5 µM 5-
fluoro-2′-deoxyuridine at a density of 8 x 106 cells/dish. A third of the media was 
exchanged twice per week. Neurons were harvested for proteome isolation after 16 
days in vitro, at which point cultures contained <3% of non-neuronal cells.  
Microglia were derived from mixed glial cultures prepared from postnatal day 2-3 
mouse forebrains from the different MAGL conditional lines as needed. Briefly, 
forebrains were dissected, stripped of meninges, and digested in papain/DNAse (20 
minutes at 37 °C) followed by 0.25% trypsin (15 min at 37 °C) and trituration. 
Dissociated cells were then cultured for 10 days in poly-D-lysine coated T75 tissue 
culture flasks in DMEM media supplemented with 10% FBS and 2 mM glutamine. After 
establishment of the astrocyte monolayer, the flasks were shaken for 2 h at 180 rpm to 
obtain the loosely attached microglia. Microglia were subsequently plated onto 10 cm 
dishes at a density of 3 x 106 cells/dish in Macrophage-SFM media (Gibco) 
supplemented with 1% FBS and 0.5 ng/ml of granulocyte macrophage-colony 
stimulating factor. The purity of these microglia cultures was >99% (Figure S1F), and 
cells were allowed to sit for at least 72 h prior to harvesting them for proteome isolation.  
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Following isolation of microglia, established mixed glial cultures were treated with 
8 µM cytosine-arabinoside for 3-5 days to kill actively dividing cells (e.g. microglia, 
fibroblast), and generate an astrocyte monolayer with >85% purity (Figure S1F). These 
astrocytes were subsequently plated onto poly-D-lysine coated 10 cm dishes in DMEM 
media supplemented with 10% FBS and 2 mM glutamine, and allowed to become 
confluent. Upon reaching confluence, astrocytes were harvested for subsequent 
proteome isolation. 
 
Preparation of mouse tissue and cell proteomes. 8-week old mice were 
anaesthetized with isoflurane, killed by cervical dislocation, and tissues harvested, 
immediately flash frozen in liquid nitrogen and kept frozen at −80 °C until use. For 
preparation of proteomes, tissues were homogenized in cold PBS using a bullet blender 
(Next Advance, Inc.) as per the manufacturer’s instructions, followed by a low-speed 
spin (1,400 x g, 5 min) to remove debris, and ultracentrifugation (100,000 x g, 45 min) to 
separate membrane and cytosolic fractions. The supernatant was removed and saved 
as the soluble proteome, while the pellet was washed and resuspended in cold PBS by 
sonication and saved as the membrane proteome. Total protein concentration for each 
proteome was determined using a Bio-Rad Dc Protein Assay kit, and proteomes were 
kept at -80C until further use.  
 
Activity-based protein profiling analysis. 50µL of 1mg/ml tissue membrane proteome 
were incubated with the broad-spectrum serine hydrolase probe FP-rhodamine (1 µM 
final concentration) for 30 min at room temperature. When necessary, proteomes were 
pre-treated with inhibitors for 1 hr at 37°C prior to addition of FP-rhodamine. Probe 
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labeling was terminated by quenching with 4x SDS/PAGE loading buffer, and labeled 
proteome samples were separated by SDS-PAGE [10% (wt/vol) acrylamide] and 
visualized by in-gel fluorescence scanning using a flatbed fluorescence scanner (Hitachi 
FMBio IIe). Rhodamine fluorescence is shown in grayscale, and optical density of the 
signals was determined using Image-J. 
 
Western blotting. For western blotting, proteome samples were separated by SDS-
PAGE [10% (wt/vol) acrylamide] and gels were transferred to a nitrocellulose 
membrane. The membrane was then blocked in 5% milk in 0.5% TBS-Tween and 
incubated overnight with MAGL (1:1000, rabbit, gift from Dr. Ken Mackie, Indiana 
University), Na+/K+ ATPase (1:1000, rabbit, Millipore), GluN1 glutamate receptor 
(1:1000, mouse, NeuroMab), α1 GABAA receptor (1:1000, mouse, NeuroMab), beta 
tubulin 3 (Tuj; 1:1000, chicken, Aves), GFAP (1:1000, rabbit, Abcam), and Iba1 (1:1000, 
rabbit, Wako) primary antibodies. Following incubation with IRdye680 secondary 
antibody (1:5,000, Licor Biosciences), membranes were visualized with a Licor Odyssey 
CLx near-infrared imager.  
 
2-AG substrate hydrolysis assay. In vitro 2-AG hydrolysis was determined by liquid 
chromatography-mass spectrometry (LC-MS) monitoring of the generation of AA 
product. Briefly, 10 µg of brain membrane proteomes or primary cells from MAGL-T, -N, 
-A, and –MKO mice and wild-type littermates (2-month old, N=4/5 per genotype) were 
incubated with 100 µM 2-AG in PBS (100µl final volume) for 10 min. Reactions were 
quenched by addition of 300 µl of 2:1 (vol/vol) CHCl3:MeOH doped with 0.5 nmoles of 
AA-d8 lipid standard, vortexed to mix, and spun at 2000 rpm x 5 min to separate 
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phases. The bottom organic phases was extracted and 20 µl were injected onto an 
Agilent 6460 triple quadrupole (QQQ) MS.  Chromatography was performed on a 50 × 
4.60 mm 5-µm Gemini C18 column (Phenomenex) coupled to a guard column (Gemini; 
C18; 4 × 3.0 mm; Phenomenex SecurityGuard cartridge). The LC method consisted of 
0.5 mL/min of 100% buffer A [95:5 (vol/vol) H2O:MeOH plus 0.1% (vol/vol) ammonium 
hydroxide] for 1.5 min, 0.5 mL/min linear gradient to 100% buffer B [65:35:5 (vol/vol) 
iPrOH:MeOH:H2O plus 0.1% (vol/vol) ammonium hydroxide] over 5 min, 0.5 mL/min 
100% buffer B for 3 min, and equilibration with 0.5 mL/min 100% buffer A for 1 min 
(10.5 min total run time). MS analysis was performed in negative scanning mode with 
an electrospray ionization (ESI) source using the precursor to product ion transition and 
collision energies for AA and AA-d8 shown in Table S1. Dwell times for each lipid were 
set to 100 ms, and the following MS parameters were used: capillary voltage = 3.5 kV, 
drying gas temperature = 350 °C, drying gas flow rate = 9 L/min, and nebulizer 
pressure= 50 psi, sheath gas temperature = 375 °C, and sheath gas flow rate = 12 
L/min. AA release was quantified by measuring the area under the peak in comparison 
with the AA-d8 internal standard and correcting for non-enzymatically formed AA 
present in heat inactivated (10 min at 90 °C) control reactions, and relative 2-AG 
hydrolytic activity for conditional MAGL–/– proteomes was calculated by comparing to 
activity of wild-type proteomes. 
 
Slice preparation and electrophysiology. Mice were anaesthetized by isoflurane 
inhalation and decapitated. Parasagittal cerebellar slices (250 µm thick) were prepared 
from 10- to 14-day-old mice, and transverse hippocampal slices were prepared from 20- 
to 30-day-old mice. Slices were prepared at 4-6°C in a sucrose-based solution 
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containing (in mM): 78 NaCl, 68 sucrose, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 2 CaCl2, 
2 MgCl2 and 25 glucose. Slices were incubated for 30-40 min in sucrose solution and 
then transferred and stored in the artificial cerebrospinal fluid (ACSF) containing (in 
mM): 119 NaCl, 2.5 KCl, 2.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 26 NaHCO3, and 10 
glucose. All solutions were saturated with 95% O2 and 5% CO2. 
Whole-cell voltage-clamp recordings were made from cerebellar Purkinje cells 
(PCs) and hippocampal CA1 pyramidal neurons as described previously (Pan et al., 
2009; Zhong et al., 2011). Excitatory postsynaptic currents (EPSCs) were recorded from 
cerebellar Purkinje cells while parallel fibers (PFs) were stimulated with a bipolar 
tungsten stimulation electrode (WPI) that was placed in the molecular layer. PF-EPSCs 
showed graded responses and exhibited paired-pulse facilitation (30-50 ms intervals) 
(Kreitzer and Regehr, 2001). GABAA receptor blocker picrotoxin (50 µM) was present in 
the ACSF. Glass pipettes (3-5 MΩ) were filled with an internal solution containing (in 
mM): 130 cesium methanesulfonate, 10 CsCl, 5 QX-314, 10 HEPES, 0.2 EGTA, 2 
MgCl2, 4 Mg-ATP, 0.3 Na2GTP, and 10 Na2-phosphocreatine (pH 7.2 with CsOH). 
EPSCs were evoked by electrical stimulation at 4 s intervals. DSE was induced by a 
brief depolarization (1 s from -70 mV to 0 mV). Inhibitory postsynaptic currents (IPSCs) 
were recorded from CA1 pyramidal neurons in hippocampal slices. AMPA receptor 
antagonist CNQX (20 µM) and NMDA receptor antagonist D-2-amino-5-
phosphonovaleric acid (D-AP-5, 20 µM) were present in the ACSF. The pipettes were 
filled with an internal solution containing (in mM): 100 K-gluconate, 50 KCl, 0.1 CaCl2, 1 
EGTA-Na4, 2 MgCl2, 2 Mg-ATP, 0.3 Na2GTP, and 10 HEPES at pH 7.2 (with KOH). To 
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induce DSI, the CA1 pyramidal neurons were depolarized from -70 mV to 0 mV for 5 s, 
and IPSCs were evoked at 4 s intervals. 
 
CB1R cross-tolerance in vivo behavioral assays. To examine CB1R cross-tolerance 
in MAGL-TKO, -NKO and -AKOs and wild-type littermates, two month-old mice (N=7-8 
per genotype, mixed sex) were evaluated for cannabimimetic responses following 
injection with WIN55,212-2. Specifically we assessed catalepsy in the bar test, 
antinociception in the tail immersion test at 56 °C, and hypothermia. Briefly, catalepsy 
was assessed on a bar 0.7 cm in diameter placed 4.5 cm off of the ground. The mouse 
was placed with its front paws on the bar and the amount of time it remained immobile 
(with the exception of respiratory movements) within a 60 s window was recorded. The 
assay was stopped after 60 s, or after the fourth time the mouse moved off the bar. 
Note that no differences in catalepsy were seen for any of our conditional MAGL–/– lines 
and these data are not shown. Nociception was assessed by holding each mouse and 
submerging 1 cm of its tail into a 56 °C water bath. The latency for the mouse to 
withdraw its tail was scored. Hypothermia was determined by measuring each mouse’s 
rectal temperature with a rectal thermometer. Note that to reduce the number of mice 
required for these studies, we evaluated dose-response relationships using a 
cumulative dosing regimen in which baseline behavioral endpoints were assessed, 
injections were given every 40 min, and subjects were evaluated for each measure 30 
min after each injection, with the entire dose-response assessment being completed in 
less than 4 h. 
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Agonist-Stimulated [35S]GTPγS Binding. Tissue samples were thawed and 
homogenized in 20 ml ice-cold Buffer A (50 mM Tris-HCl, 3 mM MgCl2, 1 mM EGTA, 
pH 7.4) on the day of assay.  The sample was then centrifuged at 48,000 x g at 4°C for 
10 min, resuspended in Buffer B (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA, 100 mM 
NaCl, pH 7.4), and centrifuged at 48,000 x g.  Membranes were resuspended in Buffer 
B, protein concentrations were determined, and membranes were pre-incubated for 10 
min at 30 ˚C with adenosine deaminase (4 mU/ml) to remove endogenous adenosine.  
Membranes (5-10 µg) were then incubated at 30°C for 2 hr in Buffer A with 1 g/L bovine 
serum albumin (BSA), 0.8 mU/ml adenosine deaminase, 30 µM GDP, 0.1 nM 
[35S]GTPγS and varying concentrations of CP55,940 in a 0.5 ml total volume.  Basal 
binding was determined in the absence of agonist, and nonspecific binding was 
measured in the presence of 20 µM unlabeled GTPγS. All data reported are derived 
from specific binding. The reaction was terminated by rapid filtration under vacuum 
through GF/B glass fiber filters, followed by 3 washes with cold (4°C) Tris buffer (50 mM 
Tris-HCl, pH 7.4).  Bound radioactivity was determined by liquid scintillation 
spectrophotometry at 95% efficiency for 35S after extraction of the filters in scintillation 
fluid. 
 
Lipid measurements. Metabolite levels were quantified by multiple reaction monitoring 
(MRM) of each lipid species using and Agilent 6460 QQQ instrument. 2 month-old 
MAGL-TKO, -NKO, -AKO, and -MKOs were injected intraperitoneally (ip) with LPS in 
PBS (20mg/kg) or with PBS vehicle alone. 6 hours post-injection, mice were sacrificed 
by cervical dislocation, and their brains rapidly removed and immediately flash frozen in 
liquid nitrogen. One brain hemisphere was then weighted and dounce homogenized in 8 
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ml of cold 2:1:1 (v/v/v) CHCl3:MeOH:PBS doped with the following lipid standards: 1 
nmol of 2-AG-d5, 0.5 nmol of AEA-d4, 1 nmol of AA-d8 and 0.5 nmol of PGE2-d9. Note 
that brains were not allowed to thaw prior to contact with organic solvents. Brain 
homogenates were vortexed and centrifuged at 2,000 rpm for 5 min. The organic 
bottom fraction was carefully collected, and the remaining solution was re-extracted by 
adding another 2 ml of CHCl3 with 20µl of formic. The organic fractions from both 
extractions were combined, and dried under a nitrogen stream. Lipids were resolubilized 
in 200µl of 1:1 (v/v) CHCl3:MeOH, 10 µl of which were injected for mass spectrometry 
analysis.  
For cultured microglia LPS studies, 3 x 106 cells were treated with 100 ng/ml of 
LPS for 4 hrs. Lipids were then extracted from cells by scraping them from dish in 1.1 ml 
of cold PBS, of which 100 µl were saved to measure protein concentration for 
normalization, prior to re-scraping with 1 ml of cold MeOH. The 2 mL of cell lysate were 
then transferred to 2 mL of CHCl3 with 20µl of formic acid and the following lipid 
standards: 0.5 nmol of 2-AG-d5, 0.25 nmol of AEA-d4, 0.5 nmol AA-d8, and 0.5 nmol of 
PGE2-d9. After centrifugation at 2,000 rpm for 5 min, the organic bottom fraction was 
carefully collected and dried under a nitrogen stream. Lipids were resolubilized in 140µl 
of 1:1 (v/v) CHCl3:MeOH, 20 µl of which were injected for mass spectrometry analysis. 
LC separation of lipid metabolites was performed on a 50 × 4.60 mm 5-µm 
Gemini C18 column (Phenomenex) coupled to a guard column (Gemini; C18; 4 × 3.0 
mm; Phenomenex SecurityGuard cartridge). Mobile phase A consisted of 95:5 (vol/vol) 
H2O:MeOH and mobile phase B consisted of 60:35:5 (vol/vol) iPrOH:MeOH:H2O, with 
0.1% formic acid or ammonium hydroxide added to both mobile phases to assist in ion 
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formation in positive and negative ionization modes, respectively. For the targeted 
detection of MAGs and NAEs in positive mode, each run started at 0.1 mL/min of 100% 
A. At 5 min, the solvent was immediately changed to 60% B with a flow rate of 0.4 
mL/min and increased linearly to 100% B over 15 min. 100% B was allowed to flow at 
0.5 mL/min for an additional 8 min prior to equilibrating for 3 min with 100% A at 0.5 
mL/min.  For targeted detection of eicosanoids and fatty acids in negative mode, each 
run started at 0.1 mL/min of 100% A. At 3 min, the flow rate was increased to 0.4 
mL/min with a linear increase of solvent B to 100 % over 17 min. 100% B was allowed 
to flow at 0.5mL/min for 7 min prior to equilibrating for 3 min with 100% A at 0.5 mL/min. 
MS analysis was performed in either positive or negative scanning mode with an 
electrospray ionization (ESI) source, and the precursor to product ion transitions and 
collision energies for different metabolites shown in Table S1 were used. Dwell times 
for each lipid were set to 100 ms, and the following MS parameters were used: capillary 
voltage = 3.5 kV, drying gas temperature = 350 °C, drying gas flow rate = 9 L/min, and 
nebulizer pressure= 50 psi, sheath gas temperature = 375 °C, and sheath gas flow rate 
= 12 L/min. Metabolite species were quantified by measuring the area under the peak in 
comparison with the appropriate unnatural internal standard and normalizing for wet 
tissue weight.  
 
Cytokine analysis. Cytokines were measured using a DuoSet ELISA kit (R&D 
systems) as per the manufacturer's instructions. Brains  were homogenized in cold PBS 
in the presence of 1 x protease inhibitor cocktail (Roche) using a bullet blender (Next 
Advance, Inc.), followed by a low-speed spin (1,400 x g, 5 min) to remove debris, and 
ultracentrifugation (100,000 x g, 45 min) to separate membrane and cytosolic fractions. 
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The supernatant from this ultracentrifugation (the mouse brain soluble proteome) was 
used in the assay. For cultured microglia, 100 µl of media were used in the assay. 
 
Neuron-astrocyte transwell co-culture studies. Neurons and astrocytes were co-
cultured in 10 cm transwell dishes with polycarbonate membrane permeable supports 
with a 0.4mm pore size (Costar). Purified astrocytes (see above) were plated onto the 
membrane permeable supports following coating with poly-D-lysine, and maintained in 
DMEM media supplemented with 10% FBS and 2 mM glutamine until they reached 
confluency (5-7 days). At this point astrocytes on the membrane permeable supports 
were transferred to a separate 10 cm dish with neurobasal medium containing 2% B27 
supplement, 2 mM glutamine, and 5 µM 5-fluoro-2′-deoxyuridine for 24 hours. During 
this time cortico-hippocampal neurons were prepared from embryonic day 18 MAGL+/+ 
or MAGL–/– mice as described above and plated onto the transwell dishes at a density of 
8 x 106 cells/dish. After allowing neurons to settle overnight, astrocytes on the 
membrane permeable supports were returned to the transwell dishes and co-cultures 
were maintained for 16 days in vitro. A third of the media was changed two times per 
week.  
For AA-d8 labeling experiments, co-cultures were allowed to mature for 12 days 
at which point astrocytes on the membrane permeable supports were transferred to a 
separate 10 cm dish for 48 hours. AA-d8 conjugated to BSA prepared as described 
elsewhere (Rouzer et al., 2006) was then added to the media of neurons or astrocytes 
as needed at a final concentration of 2.5 mg/mL of BSA and 10 µg/ml of AA-d8. After 48 
hours of incubation, cells were thoroughly washed with warm media, the media fully 
replaced, and neurons and astrocytes co-cultured together for another 36 hours. 
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Lipids were extracted from each cell type separately by scraping cells from the 
transwell dish (for neurons) or from the permeable membrane support being held in a 
separate 10 cm dish (for astrocytes) in 1 ml of cold PBS and 1 ml of cold MeOH. The 2 
mL of cell lysate were then transferred to 2 mL of CHCl3 with 20µl of formic acid and the 
following lipid standards: 1 nmol of 2-AG-d5, 0.5 nmol of AEA-d4, AA-d8 (replaced with 
1nmol of PDA in AA-d8 labeling experiments) and 0.5 nmol of PGE2-d9. After 
centrifugation at 2,000 rpm for 5 min, the organic bottom fraction was carefully collected 
and dried under a nitrogen stream. Lipids were resolubilized in 140µl of 1:1 (v/v) 
CHCl3:MeOH, 20 µl of which were injected for mass spectrometry analysis. 5 ml of 
media from each transwell dish were also extracted in an analogous manner by 
combining with 5 ml of MeOH and 10 ml of CHCl3. 
 
Immunohistochemistry. Mice were deeply anesthetized using isoflurane and perfused 
with PBS followed by 4% (wt/vol) paraformaldehyde. Brains were then carefully 
dissected, postfixed in 4% paraformaldehyde overnight, cryoprotected in 30% (wt/vol) 
sucrose, and rapidly frozen on dry ice. Free floating coronal sections 40 µm in thickness 
were cut on a Leica CM1850 cryostat. For examination of microglial activation, frozen, 
free-floating sections were blocked with Bloxall (Vector labs, 10 min) and 0.2% Triton-
X100 and 3% goat serum in PBS (blocking solution, 1 hr) prior to O/N incubation at 4 °C 
with a rabbit anti-ionized calcium-binding adaptor molecule (Iba)1 primary antibody 
(1:500 dilution in blocking solution; Wako). Sections were then incubated with 
secondary antibody (anti-rabbit biotin; Vector Laboratories; 1:300 dilution of 1.5 mg/mL 
stock) in 0.5% (wt/vol) BSA in 0.1 M PB for 1 h at room temperature and developed with 
ABC Elite Vectastain (Vector Laboratories). After staining, sections were mounted in 
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Permount and imaged using a Leica SCN400 whole slide scanner. Images were 
processed using ImageJ and Gimp using global adjustments in brightness and contrast. 
Iba1-positive microglia were quantified in matching sections from at least 5 mice per 
genotype using ImageJ particle analyzer. For examination of cre-induced expression of 
tdTomato, frozen, free-floating sections were blocked with 0.2% Triton-X100 and 3% 
goat serum in PBS (blocking solution, 1 hr) prior to O/N incubation at 4 °C with rabbit 
anti-NeuN (1:500; Abcam), rabbit anti-GFAP (1:500; Abcam) or a rabbit anti-Iba1 
(1:500; Wako) primary antibodies. Sections were then incubated with secondary 
antibodies (anti-rabbit Alexa 488; Jackson Immunoresearch; 1:300 dilution) in blocking 
solution for 1 h at room temperature. After staining, sections were mounted in 
Vectashield hardset (Vector laboratories) and imaged using a Zeiss LSM 780 scanning 
confocal microscope. Images were processed in Zen, ImageJ, and Photoshop using 
global adjustments in brightness and contrast. TdTomato positive neurons, astrocytes, 
and microglia were quantified in matching sections from 2 mice per genotype using 
ImageJ. 
 
Data Analysis and Statistics: Data are shown as the mean ± SEM. All statistical 
analyses were conducted using Excel or GraphPad Prism. A Student’s t test (unpaired, 
two-tailed) was used to determine differences between two groups. A P value less than 
0.05 was considered significant. For multi-group comparisons, 1-way ANOVA with post 
hoc Sidak’s multiple comparison test was computed using a P-value threshold of 0.05. 
For electrophysiology experiments, data are presented as the mean ± SEM. 
EPSC amplitudes were normalized to the baseline. The decay time constant (τ) of DSE 
was measured using a single exponential function of y = y0 + k × exp (–x/τ). The 
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magnitude of DSE was calculated as follows: DSE(%) = 100 x [1- (mean of 3 EPSCs 
after depolarization/mean of 5 EPSCs before depolarization)]. Values of 2-3 DSE trials 
were averaged for each neuron. Data sets were compared with Student's t-test. Results 
were considered to be significant at p < 0.05. 
 For [35S]GTPγS experiments, binding was assayed in triplicate and data are 
reported as mean ± SEM. % Stimulation = (agonist-stimulated – basal [35S]GTPγS 
binding) / basal [35S]GTPγS binding x 100%. Concentration-effect curves were analyzed 
by nonlinear regression to yield Emax and EC50 values using GraphPad/Prism 5.0 
software. All data were subjected to ANOVA with post-hoc Dunnett’s test to determine 
significant differences between conditional knockout and control mice using 
GraphPad/Prism 5.0 software. 
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Table S1, related to Figures 1, 4, and 5. Precursor to product ion transition and 
collision energies for all lipids measured by MRM-MS. 
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